Reported about 20 hours ago
Mersana Therapeutics showcased encouraging interim Phase 1 clinical data for its cancer drug Emi-Le at the ASCO 2025 meeting in Chicago. The drug, aimed at various cancers including triple-negative breast cancer, demonstrated a favorable safety profile consistent with earlier findings, with no new safety issues reported. The company is focusing on expanding treatment options for patients with unmet needs, particularly those previously treated with a specific type of cancer therapy.
Source: YAHOO